What Are the Current Exon Skipping Therapies Available?
Several exon skipping therapies have received regulatory approval. For instance, eteplirsen (marketed as Exondys 51) has been approved for the treatment of DMD. These therapies are designed for specific exon mutations, such as exon 51 skipping in the case of eteplirsen.